Overview Dividends

(RGNX) Regenxbio - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75901B1070

Gene,Therapy,AAV,Platform,Pipeline

RGNX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 13.98%
EPS Trend (3Y Correlation): 47.1%

RGNX Revenue

Revenue Growth (3Y CAGR): -1.90%
Revenue Trend (3Y Correlation): 28.4%

Risk via 10d forecast
Volatility	67.0%
Value at Risk 5%th	105%

Reward
Sharpe Ratio	0.38
Alpha Jensen	-13.37

Character
Hurst Exponent	0.341
Beta	1.147

Drawdowns 3y
Max DD	78.42%
Mean DD	40.88%

Description: RGNX Regenxbio October 24, 2025

Regenxbio Inc. (NASDAQ:RGNX) is a clinical-stage biotech that commercializes gene-therapy products using its proprietary NAV (AAV-based) delivery platform, targeting genetic disorders primarily in the United States.

Its current pipeline includes: ABBV-RGX-314 for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases (in partnership with AbbVie for non-U.S. markets); RGX-202, a Phase III candidate for Duchenne muscular dystrophy; RGX-121 for mucopolysaccharidosis type II; RGX-111 for mucopolysaccharidosis type I; RGX-181 for late-infantile neuronal ceroid lipofuscinosis type 2; and RGX-381 for the ocular manifestations of CLN2 disease.

Beyond its own product development, Regenxbio licenses the NAV platform to external biotech and pharma firms, generating non-dilutive revenue streams and expanding the technology’s market footprint.

Key quantitative indicators (as of the latest 10-Q) show a cash balance of roughly $250 million, a runway of about 18 months at current burn, and a market capitalization near $1.2 billion, placing the company in the mid-cap tier of the gene-therapy sector, which is projected to grow at a CAGR of 12-15 % through 2030 driven by rising FDA approvals and payer acceptance of AAV-based treatments.

Investors should note that the success of RGX-202’s Phase III readout and the ability to secure additional licensing deals are the primary catalysts that could materially shift the valuation; conversely, any setbacks in trial endpoints or platform safety concerns would materially downgrade upside.

If you’re looking for a deeper, data-driven assessment of Regenxbio’s risk-adjusted upside, ValueRay’s analyst toolkit offers a granular breakdown of the company’s cash-flow projections and comparable peer multiples.

RGNX Stock Overview

Market Cap in USD	567m
Sub-Industry	Biotechnology
IPO / Inception	2015-09-17
Return 12m vs S&P 500	-4.57%
Analyst Rating	4.42 of 5

RGNX Dividends

Currently no dividends paid

RGNX Growth Ratios

CAGR	-18.36%
CAGR/Max DD Calmar Ratio	-0.23
CAGR/Mean DD Pain Ratio	-0.45
Current Volume	515.6k
Average Volume	542.7k

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-177.9m TTM) > 0 and > 6% of Revenue (6% = 9.68m TTM)

FCFTA -0.20 (>2.0%) and ΔFCFTA 15.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 128.6% (prev 249.8%; Δ -121.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.20 (>3.0%) and CFO -103.3m > Net Income -177.9m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 2.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (51.7m) change vs 12m ago 1.75% (target <= -2.0% for YES)

Gross Margin 84.75% (prev 39.46%; Δ 45.30pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 30.89% (prev 16.24%; Δ 14.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.06 (EBITDA TTM -127.5m / Interest Expense TTM 42.1m) >= 6 (WARN >= 3)

Altman Z'' -8.16

(A) 0.39 = (Total Current Assets 332.0m - Total Current Liabilities 124.6m) / Total Assets 525.2m

(B) -2.02 = Retained Earnings (Balance) -1.06b / Total Assets 525.2m

warn (B) unusual magnitude: -2.02 — check mapping/units

(D) -2.91 = Book Value of Equity -1.06b / Total Liabilities 363.8m

Total Rating: -8.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 23.38

1. Piotroski 1.50pt = -3.50

2. FCF Yield -28.74% = -5.0

3. FCF Margin -65.88% = -7.50

4. Debt/Equity 0.47 = 2.39

5. Debt/Ebitda -0.14 = -2.50

6. ROIC - WACC (= -45.98)% = -12.50

7. RoE -78.29% = -2.50

8. Rev. Trend 28.44% = 2.13

9. EPS Trend 47.12% = 2.36

What is the price of RGNX shares?

As of November 13, 2025, the stock is trading at USD 11.60 with a total of 515,556 shares traded.
Over the past week, the price has changed by -0.09%, over one month by +2.29%, over three months by +43.21% and over the past year by +10.58%.

Is Regenxbio a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Regenxbio (NASDAQ:RGNX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 23.38 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RGNX is around 9.96 USD . This means that RGNX is currently overvalued and has a potential downside of -14.14%.

Is RGNX a buy, sell or hold?

Regenxbio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy RGNX.

Strong Buy: 6
Buy: 5
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RGNX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	29.6	154.7%
Analysts Target Price	29.6	154.7%
ValueRay Target Price	11.4	-2.1%

RGNX Fundamental Data Overview November 10, 2025

Market Cap USD = 567.5m (567.5m USD * 1.0 USD.USD)
P/S = 3.5178
P/B = 2.5011
P/EG = 0.26
Beta = 1.147
Revenue TTM = 161.3m USD
EBIT TTM = -87.0m USD
EBITDA TTM = -127.5m USD
Long Term Debt = 82.0m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 9.07m USD (from shortTermDebt, last quarter)
Debt = 76.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.7m USD (from netDebt column, last quarter)
Enterprise Value = 369.8m USD (567.5m + Debt 76.5m - CCE 274.2m)
Interest Coverage Ratio = -2.06 (Ebit TTM -87.0m / Interest Expense TTM 42.1m)
FCF Yield = -28.74% (FCF TTM -106.3m / Enterprise Value 369.8m)
FCF Margin = -65.88% (FCF TTM -106.3m / Revenue TTM 161.3m)
Net Margin = -110.3% (Net Income TTM -177.9m / Revenue TTM 161.3m)
Gross Margin = 84.75% ((Revenue TTM 161.3m - Cost of Revenue TTM 24.6m) / Revenue TTM)
Gross Margin QoQ = 80.75% (prev 57.33%)
Tobins Q-Ratio = 0.70 (Enterprise Value 369.8m / Total Assets 525.2m)
Interest Expense / Debt = 17.21% (Interest Expense 13.2m / Debt 76.5m)
Taxrate = -0.0% (0.0 / -227.1m)
NOPAT = -87.0m (EBIT -87.0m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 2.66 (Total Current Assets 332.0m / Total Current Liabilities 124.6m)
Debt / Equity = 0.47 (Debt 76.5m / totalStockholderEquity, last quarter 161.5m)
Debt / EBITDA = -0.14 (negative EBITDA) (Net Debt 17.7m / EBITDA -127.5m)
Debt / FCF = -0.17 (negative FCF - burning cash) (Net Debt 17.7m / FCF TTM -106.3m)
Total Stockholder Equity = 227.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.88% (Net Income -177.9m / Total Assets 525.2m)
RoE = -78.29% (Net Income TTM -177.9m / Total Stockholder Equity 227.2m)
RoCE = -28.13% (EBIT -87.0m / Capital Employed (Equity 227.2m + L.T.Debt 82.0m))
RoIC = -34.91% (negative operating profit) (NOPAT -87.0m / Invested Capital 249.2m)
WACC = 11.07% (E(567.5m)/V(644.0m) * Re(10.24%) + D(76.5m)/V(644.0m) * Rd(17.21%) * (1-Tc(-0.0)))
Discount Rate = 10.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.38%
Fair Price DCF = unknown (Cash Flow -106.3m)
EPS Correlation: 47.12 | EPS CAGR: 13.98% | SUE: 0.43 | # QB: 0
Revenue Correlation: 28.44 | Revenue CAGR: -1.90% | SUE: 0.66 | # QB: 0

Additional Sources for RGNX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle